Clinical Study
The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients
Table 1
Baseline characteristics of patients populations at treatment of CAMR.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CAMR: chronic antibody mediate rejection; BMI: body mass index; cGN: chronic glomerulonephritis; Cr: creatinine; MDRD eGFR: estimated GFR using the Modification of Diet in Renal Disease Study equation; HLA-DSA: donor specific anti-HLA antibody. |